ERBB2 and gastric cancer: Indeed, among the targeted drugs approved by the FDA for GC treatment (Trastuzumab, fam-trastuzumab, pembrolizumab, disitamab, ramucirumab, Keytruda and Opdovo), most target dysregulated signal transduction factors such as epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor receptor (VEGFR)[12].